FK 788

Drug Profile

FK 788

Alternative Names: FK-788

Latest Information Update: 19 Jan 2012

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antivirals; Carbamates
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 31 Mar 2006 Astellas Pharma completes a phase II trial in Hepatitis C in USA (NCT00047814)
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 31 Oct 2002 Phase-II clinical trials in Hepatitis C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top